Literature DB >> 1795036

Use of thermospray liquid chromatography-mass spectrometry to aid in the identification of urinary metabolites of a novel antiepileptic drug, Lamotrigine.

M V Doig1, R A Clare.   

Abstract

The use of thermospray liquid chromatography-mass spectrometry allowed the structural elucidation of a number of urinary metabolites of Lamotrigine, 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine, formed after administering the drug to man, Cynomolgus monkey and rabbit. This data when combined with the data obtained from high-performance liquid chromatography with radiochemical detection enabled us to determine the types and amounts of unchanged drug and metabolites excreted in urine by man and a number of laboratory animal species. This technique was particularly useful as it highlighted a previously unknown fact that Lamotrigine is metabolised to form two different N-glucuronides, one of which is resistant to cleavage in vitro by a crude beta-glucuronidase preparation from Helix pomatia.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1795036     DOI: 10.1016/s0021-9673(01)88448-x

Source DB:  PubMed          Journal:  J Chromatogr


  14 in total

1.  Determination of lamotrigine in human serum by high-performance liquid chromatography–tandem mass spectrometry.

Authors:  Woonhyoung Lee; Jeong-Ho Kim; Hyon-Suk Kim; Oh Hun Kwon; Byung In Lee; Kyoung Heo
Journal:  Neurol Sci       Date:  2010-12       Impact factor: 3.307

2.  A Physiologically Based Pharmacokinetic Model for Optimally Profiling Lamotrigine Disposition and Drug-Drug Interactions.

Authors:  Todd M Conner; Ronald C Reed; Tao Zhang
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2019-06       Impact factor: 2.441

Review 3.  Lamotrigine. A review of its use in childhood epilepsy.

Authors:  C R Culy; K L Goa
Journal:  Paediatr Drugs       Date:  2000 Jul-Aug       Impact factor: 3.022

4.  Childhood Epilepsy : Current Therapeutic Recommendations.

Authors:  J T Gilman; M Duchowny
Journal:  CNS Drugs       Date:  1994-03       Impact factor: 5.749

Review 5.  Lamotrigine. A review of its pharmacological properties and clinical efficacy in epilepsy.

Authors:  K L Goa; S R Ross; P Chrisp
Journal:  Drugs       Date:  1993-07       Impact factor: 9.546

6.  Pharmacokinetics of lamotrigine and its metabolite N-2-glucuronide: Influence of polymorphism of UDP-glucuronosyltransferases and drug transporters.

Authors:  Daniela Milosheska; Bogdan Lorber; Tomaž Vovk; Matej Kastelic; Vita Dolžan; Iztok Grabnar
Journal:  Br J Clin Pharmacol       Date:  2016-05-29       Impact factor: 4.335

Review 7.  Lamotrigine. An update of its pharmacology and therapeutic use in epilepsy.

Authors:  A Fitton; K L Goa
Journal:  Drugs       Date:  1995-10       Impact factor: 9.546

Review 8.  Clinical pharmacokinetics of newer antiepileptic drugs. Lamotrigine, vigabatrin, gabapentin and oxcarbazepine.

Authors:  R D Elwes; C D Binnie
Journal:  Clin Pharmacokinet       Date:  1996-06       Impact factor: 6.447

Review 9.  Lamotrigine clinical pharmacokinetics.

Authors:  B Rambeck; P Wolf
Journal:  Clin Pharmacokinet       Date:  1993-12       Impact factor: 6.447

10.  Pharmacotherapeutics of epilepsy: use of lamotrigine and expectations for lamotrigine extended release.

Authors:  Mary Ann Werz
Journal:  Ther Clin Risk Manag       Date:  2008-10       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.